Control Bionics (ASX:CBL) Research & Development: A$1.12 Mil (TTM As of Dec. 2025)


What is Control Bionics Research & Development?

Control Bionics ASX:CBL -2.30% Research & Development is A$1.12 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Control Bionics's Research & Development for the six months ended in Dec. 2025 was A$0.62 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.12 Mil.

Control Bionics  (ASX:CBL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Control Bionics Research & Development Related Terms

Control Bionics Research & Development Historical Data

* Premium members only.

The historical data trend for Control Bionics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Control Bionics Research & Development Chart

Control Bionics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial 0.17 0.33 0.23 1.72 1.07

Control Bionics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 1.54 0.57 0.50 0.62

Control Bionics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$1.12 Mil mean?
Control Bionics (ASX:CBL) has a Research & Development of A$1.12 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Control Bionics and its competitors.
Is Control Bionics' Research & Development too high?
Control Bionics' current Research & Development is A$1.12 Mil.
How does Control Bionics' Research & Development compare to ABT and SYK?
Control Bionics' Research & Development of A$1.12 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Control Bionics and its competitors. Control Bionics's current Research & Development is A$1.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.09 — trading 183.3% above its estimated fair value. The current Research & Development is A$1.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Research & Development is A$1.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Control Bionics Business Description

Address 11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.